Business Wire

IL-GE-TRANSPORTATION

18.9.2018 08:02:12 CEST | Business Wire | Press release

Share
GE Transportation Announces New High-Speed Engine Program

GE Transportation (NYSE:GE) announced today at InnoTrans 2018 a new high-speed diesel engine program, which will serve the locomotive, marine and power generation segments. The engine platform will provide improved fuel efficiency and reliability, as well as lower lifecycle costs.

“This new, high-speed engine will be a game changer for our customers,” said Dominique Malenfant, Vice President of Global Technology for GE Transportation. “They will enjoy reduced operating costs and increased availability with this engine. It will generate annual savings for customers of up to $12,000 in diesel and $4,000 in services.”

Compared to similarly sized locomotive engines, GE Transportation’s high-speed engine will offer a 5 percent better total cost of ownership. It will be 5 percent more fuel efficient, saving customers more than 6,000 gallons of diesel per year. The engine also will reduce maintenance costs by 10 percent and provide 184-day service intervals. Overhauls will be on 10-year intervals.

“We are leveraging our expertise and technology in the medium-speed engine segment to create a smaller, power-dense engine platform for products such as shunters and light-weight locomotives,” said Malenfant. “This new program will open up new segments for our business.”

The combination of a powerful engine at a smaller size and weight makes the platform ideal in regions like Asia, Africa, South America, Australia and New Zealand, which require lighter locomotives. Kazakhstan Temir Zholy (KTZ) will be the first to use the new engine to power the 300 shunter locomotives ordered earlier this year. GE Transportation will deliver the first shunter to KTZ in 2019.

“GE technology is the primary driver for developing Kazakhstan’s rail industry,” said Kanat Alpysbayev, Chairman of KTZ. “The high-speed engine will provide our new shunter fleet with the performance and maintainability needed to conduct our operations in a cost-effective manner.”

GE Transportation is developing the platform for application in multiple segments. The company is designing the high-speed diesel engine in 12- and 16-cylinder configurations with a maximum-rated horsepower of 2,500 and 3,300 respectively. At 7.40 lbs. per horsepower, the design will be 40 percent more powerful per pound compared to a medium-speed engine. It also will be digitally ready with remote prognostic capabilities to improve performance and reliability. Additionally, the engine design will meet the emission standards for both the European Union’s Stage III A/B and the International Union of Railways’ UIC Stage I/II.

The core architecture of the engine platform was jointly developed with GE Distributed Power, incorporating decades of high-speed engine experience across the Jenbacher and Waukesha product lines. GE Distributed Power is targeting a serialization of the technology to introduce a range of stationary gas engine operating potentially as soon as 2020.

Visit the GE Transportation InnoTrans 2018 webpage to learn more about this week’s announcements, demos and displays. The GE Transportation booth is located at Hall 3.2, Stand 401.

About GE Transportation

At GE Transportation , we move the world and improve the world. We are a global technology leader and supplier of equipment, services and digital solutions to the rail, mining, marine, stationary power and drilling industries. Our innovations help customers deliver goods and services with greater speed and savings using our advanced manufacturing techniques and connected machines. GE Transportation is headquartered in Chicago, IL, and employs approximately 9,000 employees worldwide.

Contact:

GE Transportation Deia Campanelli 773-297-0482 deia.campanelli@ge.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye